CuATSM
CuATSM structure
|
Common Name | CuATSM | ||
|---|---|---|---|---|
| CAS Number | 68341-09-3 | Molecular Weight | 321.91 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C8H14CuN6S2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
Use of CuATSMCuATSM is a highly potent radical-trapping antioxidant (RTA) and inhibitor of (phospho)lipid peroxidation, thereby accounting for its (their) ability to inhibit ferroptosis. |
| Name | 0YDK1H9L3A |
|---|---|
| Synonym | More Synonyms |
| Description | CuATSM is a highly potent radical-trapping antioxidant (RTA) and inhibitor of (phospho)lipid peroxidation, thereby accounting for its (their) ability to inhibit ferroptosis. |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C8H14CuN6S2 |
|---|---|
| Molecular Weight | 321.91 |
| Exact Mass | 321.001740 |
| Appearance of Characters | powder |
| Storage condition | 2-8°C |
| Water Solubility | DMSO: soluble10mg/mL, clear |
| RIDADR | NONH for all modes of transport |
|---|---|
| WGK Germany | 3 |
|
Zn II(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism.
Neurobiol. Dis. 81 , 20-4, (2015) Mutations in the metalloprotein Cu,Zn-superoxide dismutase (SOD1) cause approximately 20% of familial cases of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease for which effectiv... |
|
|
Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis.
J. Neurosci. 34(23) , 8021-31, (2014) Mutations in the metallo-protein Cu/Zn-superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS) in humans and an expression level-dependent phenotype in transgenic rodents. We show that o... |
|
|
Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.
Amyotroph. Lateral Scler. Frontotemporal Degener. 14(7-8) , 586-90, (2013) Our objective was to assess the copper(II) complex of diacetylbis(4-methylthiosemicarbazone) [Cu(II)(atsm)] for its preclinical potential as a novel therapeutic for ALS. Experimental paradigms used we... |
| Copper(2+) (2E,2'E)-2,2'-[(2E,3E)-2,3-butanediylidene]bis(N-methylhydrazinecarbimidothioate) |
| Hydrazinecarbothioamide, 2,2'-[(1E,2E)-1,2-dimethyl-1,2-ethanediylidene]bis[N-methyl-, copper(2+) salt, (2E,2'E)- (1:1) |
| ATSM CU-64 |
| 0YDK1H9L3A |
| Cu-ASTM |